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Background: Recent investigations suggest that serum adiponectin levels are negatively associated with
the development of aggressive prostate cancer, however, not all epigenetic studies support the inverse
association.
Methods: We analyzed serum adiponectin levels, prostate-speciﬁc antigen (PSA) levels, and outcomes of
prostate cancer screening of 2,939 participants of a PSA-based screening program conducted by a single
institute in Japan.
Results: The median body mass index (BMI) of the participants was 23.9 kg/m2, and 31% had a
BMI  25 kg/m2. The adiponectin levels were signiﬁcantly and negatively correlated with BMI
(r ¼ 0.260, P < 0.0001). However, a signiﬁcant and positive correlation was observed between adi-
ponectin levels and PSA levels (r ¼ 0.054, P ¼ 0.0061). After screening, 24 (0.82%) patients were diag-
nosed with prostate cancer. Interestingly, the adiponectin levels of the 24 prostate cancer patients
(average 9.86 mg/mL) were signiﬁcantly higher than those of the 2,817 participants with PSA levels <
4 ng/mL (average 7.63 mg/mL) (P ¼ 0.0049). However, when restricted to the eight high-risk prostate
cancer patients, the adiponectin levels did not differ from those of the participants with PSA levels <
4 ng/mL. The age-adjusted cancer detection rate of the participants was calculated by stratifying the BMI
(cut-off level 25 kg/m2) and adiponectin levels (cut-off level 6.7 mg/mL). The cancer detection rate in the
high-BMI and high-adiponectin group was 1.67%, which was the highest among all groups.
Conclusions: There was a signiﬁcant positive correlation between adiponectin levels and PSA levels. The
present ﬁndings also suggest that the incidence of low- or intermediate-risk prostate cancer might be
increased in overweight men with high serum adiponectin levels.
Copyright © 2015 Asian Paciﬁc Prostate Society, Published by Elsevier. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Prostate cancer (PCA) is the most commonly diagnosed cancer
among men in many regions of the world.1 In Asian countries,tachi General Hospital, 2-1-1,
Japan.
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ciﬁc Prostate Society, Published bincluding Japan, the incidence of PCA continues to increase.2,3 Risk
factors for PCA include age, familial history, high-fat food ingestion,
and obesity. Obesity has becomemore prevalent in most developed
countries, including Japan, and is increasingly recognized as a
major risk factor for several common types of cancer.4 Unfortu-
nately, obesity is becoming a common problem in most Asian
countries.5
Regarding the molecular pathways of obesity-associated cancer,
recent investigations revealed that several physiologically active
substances including adiponectin (APN), leptin, tumor necrosis
factor-alpha, and interleukin-6 are closely associated with they Elsevier. This is an open access article under the CC BY-NC-ND license (http://
Prostate Int 3 (2015) 87e9288development of various types of cancer.4 APN is an anti-inﬂam-
matory cytokine produced by adipose tissue (a so-called adipo-
kine), but unlike other adipokines, APN production decreases in
obesity. APN presents in plasma as a trimer, hexamer, and high-
molecular-weight multimer (HMW); among them, the HMW-APN
is known to be the most bioactive form.6
Epidemiologically, hypoadiponectinemia is not restricted to a
variety of obesity-associated benign diseases, but has been re-
ported to be a risk factor for various types of cancer, including
breast cancer, endometrial cancer, colorectal cancer, and gastric
cancers.6,7 Indeed, APN receptors are known to be expressed by
different types of cancer,8 and APN in vitro can inhibit cancer cell
proliferation.6 The precise molecular mechanism underlying the
association between hypoadiponectinemia and the development of
cancer has not been established.
A considerable number of case control studies9e16 and cross-
sectional studies17,18 testing the association of PCA with APN have
been published. In accordance with other types of cancer, most of
these investigations showed an inverse association of APN levels
and high-stage or high-grade PCA.9e13 However, some authors re-
ported that the inverse relationships were observed only in over-
weight or obese men.13,14 Moreover, some case control studies
suggested a positive correlation between APN levels and PCA after
adjustment for body mass index (BMI).14e16 In addition, unfortu-
nately, little is known about the association between APN levels
and the development of increased risk or early-stage disease, which
includes the majority of PCA cases detected by prostatic-speciﬁc
antigen (PSA)-based screening. In PSA-based screening studies,
ﬁndings regarding the association between APN levels and PSA
levels also conﬂict, ﬁnding no correlation,17 or a negative
correlation.18
To address these clinical questions, we conducted the present
large-scale cross-sectional study. We analyzed serum APN levels,
PSA levels, and outcomes of PCA screening of approximately 3,000
participants who attended the PSA-based screening program con-
ducted by a single institute. To the best of our knowledge, this is the
largest cross-sectional study for investigating the relationship be-
tween serum APN and outcomes of PCA screening.
2. Participants and methods
2.1. Participants
Between April 2008 and March 2009, 3,716 men attended the
PCA screening program as part of the annual periodic health
checkup at the Hitachi Health Care Center (HHCC). All of themwere
employees of the same company (Hitachi Ltd., Ibaraki, Japan).
During the same period, the HHCC undertook an epidemiological
study to examine the association between APN and general health.
This study was approved by the Ethics Committee (approval
number 2012-52) of Hitachi General Hospital and Japan's National
Center for Global Health and Medicine (approval number 514).
As part of the PCA screening program, the serum APN levels of
2,939menweremeasured.Written informed consent was obtained
from all participants. Therefore, both serum APN levels and PSA
levels were available for all of the participants. In the present study,
we analyzed the serum APN levels, PSA levels, and outcomes of PCA
screening of 2,939 men.
2.2. PCA screening program at HHCC
In the PCA screening, further examinations to detect PCA were
recommended to participants with PSA levels > 4.0 ng/mL. The
indication of prostate biopsy was generally based on PSA levels, the
ﬁndings of a digital rectal examination, transrectalultrasonography, and/or magnetic resonance imaging. The ﬁnal
decision of prostate biopsy was decided depending on each par-
ticipant's physician and physicianeparticipant communication. For
recheck of PSA, participants who did not have a biopsy had follow-
up examinations and were strongly recommended to have a
prostate biopsy if their PSA level was increasing. Because 106 of the
122 participants with high levels of PSA received further exami-
nations at the same institute, the decision-making process might
not have differed largely among these participants.
Basically, a repeat biopsy is recommended if the PSA level has
increased after a negative ﬁrst biopsy. The information available
from the screening program included participant age, height and
weight, and the results of a prostate biopsy, if performed. BMI was
calculated by height andweight at the PCA screening. Underweight,
normal, overweight, and obese BMIs were deﬁned as < 20 kg/m2,
20e25 kg/m2, 25e30 kg/m2, and > 30 kg/m2, respectively. The
screening data were aggregated until August 2013.
2.3. PSA and APN measurements
Serum PSA levels were assayed using an Abbott Axsym immu-
noanalyzer (Abbott Laboratories, Abbot Park, IL, USA). Total serum
APN levels were measured using a latex particle-enhanced turbi-
dimetric immunoassay (human adiponectin latex kit; Otsuka
Pharmaceutical Co., Tokyo, Japan) as described.19 The results were
highly correlated with enzyme-linked immunosorbent assay-based
methods (r ¼ 0.99).
2.4. Statistical analysis
The Pearson correlation test was used to evaluate the associa-
tions between serum APN levels and BMI and between APN levels
and PSA levels in each participant. Differences in the factors related
to cancer detection proportions at the further examination (age,
BMI, serum PSA level, serum adiponectin level, Gleason score, and
clinical stage) were tested using simple logistic regression and chi-
square tests. The cancer detection rate (CDR: the rate of the number
of prostate cancers detected by screening to the number of men
screened) was calculated for each subgroup divided by APN level
and BMI. In addition, the age-speciﬁc CDR was calculated for four
age groups (aged < 50 years, 50e59 years, 60e69 years, and > 69
years). The age-adjusted CDR was calculated based on the observed
age-speciﬁc CDR by applying serum APN measurement and PCA
screening to the age-speciﬁc populations in 2,931 participants in
2008. A P-value < 0.05 was considered signiﬁcant. All statistical
analyses were performed using the software package JMP version
10.0.2 (SAS Institute, Cary, NC).
3. Results
The proﬁles of the participants are shown in Table 1. The median
agewas 58 years (range 28e74 years). Themedian BMI was 23.9 kg/
m2 (range 15.1e38 kg/m2). The proportions of underweight,
normal, overweight, and obese men were 5.5%, 60.1%, 28.5%, and
2.3%, respectively. The median PSA level was 0.9 ng/mL (range
0.1e38.8 ng/mL). When the cut-off values of BMI and PSA were set
at 25 kg/m2 and 4 ng/mL, 907 men (32.0%) and 122 men (4.15%)
were classiﬁed to the higher BMI group and higher PSA group,
respectively. The median APN level was 6.7 mg/mL, however, it
varied from 1.0 mg/mL to 38.8 mg/mL.
All 122 men with PSA levels > 4 ng/mL attended the further
examination. Prostate biopsy was performed on 65 of the 122 men
(53%), and 24 participants were diagnosed with PCA. Twenty of
these 24 participants were diagnosed with clinical T1c disease and
the other four were diagnosed with clinical T2 disease. According to
Table 1
Proﬁle of the prostate-speciﬁc antigen screening participants.
Median (range)
Age (yr) 58 (28e74)
BMI 23.9 kg/m2 (15.1e38)
Adiponectin level 6.7 mg/mL (1.0e38.8)
PSA level 0.9 mg/mL (0.1e38.8)
No. (%)
First screening attender 2,939
BMI group
Underweight 161 (5.5)
Normal 1,766 (60.1)
Overweight 838 (28.5)
Obese 69 (2.3)
Unknown 105 (3.6)
Second screening attender 122 (4.2)
Men underwent prostate biopsy 65 (2.2)
Men diagnosed with PCA 24 (0.8)
Clinical T stage
cT1c 20
cT2a 1
cT2b 1
cT2c 2
D'Amico classiﬁcation
Low 6
Intermediate 10
High 8
BMI, body mass index; PCA, prostate cancer; PSA, prostate-speciﬁc antigen.
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ﬁed as the low- or intermediate-risk group, and the other eight
were classiﬁed as the high-risk group.
Fig. 1 represents the correlations between APN levels and BMI
and between APN levels and PSA levels among all participants. The
APN level was signiﬁcantly and negatively correlated with BMI
(r¼0.260, P< 0.0001; Fig.1A). However, a signiﬁcant and positive
correlation was observed between APN levels and PSA levels
(r ¼ 0.054, P ¼ 0.0061), as shown in Fig. 1B. When the participants
were divided by the PSA cut-off level, the difference was signiﬁcant
(P ¼ 0.0031): the mean APN levels of the participants with PSA
levels  4 ng/mL and of those with PSA levels < 4 ng/mL were
8.70 mg/mL and 7.61 mg/mL, respectively. The signiﬁcantly higher
APN levels were observed even when participants were stratiﬁed
by BMI with the cut-off level of 25 kg/m2.
As shown in Fig. 2A and 2B the, APN levels of the participants
with PSA levels  4 ng/mL were signiﬁcantly higher than those of
the participants with lower PSA levels in both groups. As expected,
when limited to the participants with PSA levels < 4 ng/mL, the14 16 18 2022 2426 28 3032 34 3638
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Fig. 1. Graphs showing the adiponectin (APN) level was negatively correlated with body m
(A) Correlations between APN level and BMI. (B) Correlations between APN levels and PSAaverage APN level of the participants with a BMI 25 kg/m2 was
signiﬁcantly lower than that of participants with a BMI < 25 kg/m2
(8.06 kg/m2 and 6.66 kg/m2, respectively, P < 0.001) and the
average PSA level of the participants with a BMI > 25 kg/m2
(average 1.05 ng/mL) was signiﬁcantly lower than that of the par-
ticipants with BMI < 25 kg/m2 (average 1.11 ng/mL; P ¼ 0.0497).
The APN levels of PCA patients (average 9.96 ng/mL) were
signiﬁcantly higher than nonprostate cancer participants (average
7.64 ng/mL; P< 0.001). Fig. 3 shows the distribution of APN levels
according to outcomes of the PCA screening program. We
compared the APN levels of the PCA patients with those of the
participants with PSA levels < 4 ng/mL and the participants who
had PSA levels  4 ng/mL but were not diagnosed with PCA. As
shown in Fig. 3, the APN levels in PCA patients (average 9.86 mg/mL)
were signiﬁcantly higher than those of the participants with PSA
levels < 4 ng/mL (average 7.63 mg/mL; P¼ 0.0049).
Interestingly, the APN levels of the participants who had PSA
levels 4 ng/mL but were not diagnosed with PCA after the further
examination were not signiﬁcantly different from those of the
participants with PSA levels < 4 ng/mL. When the PCA patients
were divided into low/intermediate-risk (n¼ 16) and high-risk
(n¼ 8) groups, the APN levels in the high-risk group (average
8.12 mg/mL) were lower than those in the low/intermediate-risk
group (average 10.73 mg/mL), however, the difference was not sig-
niﬁcant. Thus, when restricted to high-risk PCA patients, the APN
levels did not differ from those of the participants with PSA levels <
4 ng/mL.
Finally, we analyzed the impact of APN level on the age-adjusted
CDR in the present PCA screening program. In the analysis, the APN
cut-off level of 6.7 mg/mLwas used as the median level. As shown in
Table 2, the CDR of the low/intermediate-risk PCA participants
among the high APN group was higher than that of the low APN
group (0.717% and 0.294%, respectively), however, the difference
was not signiﬁcant. As expected, there was no signiﬁcant difference
in the CDRs of high-risk PCA between both APN groups. When the
participants were stratiﬁed by both BMI and APN level, the age-
adjusted CDR in the high BMIþ high APN group was 1.67%, which
was the highest among all groups (Table 2).4. Discussion
Accumulating evidence suggests that obesity is associated with
a greater risk of death from PCA.20 Several investigations showed
that the serum level of APN, a multifunctional adipokine, was
negatively associated with the development of aggressive PCA.9e13
However, not all epidemiologic studies support this inverse asso-
ciation of APN and PCA.14e16 In the present study, our extensive0 2 4 6 8 10 12 14 16 18 20
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Fig. 2. Adiponectin levels of participants stratiﬁed by prostate-speciﬁc antigen (PSA) levels and body mass index (BMI). The APN levels of the participants with PSA 4 ng/mL
(n¼ 117) were signiﬁcantly higher than those of the participants with PSA levels < 4 ng/mL (n¼ 2717) in both BMI groups: (A) BMI <25 kg/m2; and (B) BMI 25 kg/m2.
APN, adiponectin.
P = 0.0014
P = 0.0049
40
35
30
25
20
15
10
5
0
A
di
po
ne
ct
in
 (μ
g/
m
L)
PSA < 4ng/mL
(n = 2,817)
PSA > 4ng/mL,
not diagnosed with
PCA (n = 98)
- All patientswith PCA
(n = 24)
Patients with low-
orintermediate-risk
PCA (n = 16)
Patients with
high-risk PCA
(n = 8)
Fig. 3. Distribution of adiponectin (APN) levels according to the outcomes of the prostate cancer (PCA) screening. The APN levels in the PCA patients were signiﬁcantly higher than
those of the participants with prostate-speciﬁc antigen levels < 4 ng/mL, however, when restricted to the high-risk PCA patients, the APN levels did not differ from those of the
participants with prostate-speciﬁc antigen levels < 4 ng/mL. PSA, prostate-speciﬁc antigen.
Table 2
Age-adjusted cancer detection rate (CDR) among the screening participants.
CDR of low- to intermediate- and high-risk PCA according to APN level (%)
Low or intermediate-risk PCA High-risk PCA.
APN level  6.7 mg/mL 0.717 0.254
APN level < 6.7 mg/mL 0.294 0.323
CDR of PCA according to APN level and BMI (%)
BMI 25 kg/m2 BMI< 25 kg/m2
APN level  6.7 mg/mL 1.670 0.725
APN level < 6.7 mg/mL 0.577 0.633
APN, adiponectin; BMI, body mass index; PCA, prostate cancer.
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among 2,939 men who attended a PCA screening revealed several
interesting ﬁndings.
Firstly, there was a signiﬁcant positive correlation between APN
levels and PSA levels. By contrast, APN levels were inversely
correlated with BMI, which is consistent with a number of previousstudies.21 It is also well known that BMI is inversely associated with
PSA levels.22,23 The latter association is partly explained with a
hemodilution effect due to the higher blood volume of obese
men.22,23 Indeed, in the present study, when limited to participants
with PSA< 4 ng/mL, the average PSA level of the participants with
BMI 25 kg/m2 was signiﬁcantly lower than that of the partici-
pants with BMI< 25 kg/m2. When considering the association of
the three parameters of APN levels, BMI, and PSA levels, the
observed positive correlation between APN levels and PSA levels is
entirely comprehensible. However, to our knowledge, this is the
ﬁrst report to show a positive association between both
parameters.
In relevant literature, there are two cross-sectional studies that
analyzed the association between APN levels and PSA levels. Fowke
et al17 investigated 242 African-American and Caucasian men and
found no association between APN levels and PSA levels. Alokail
et al18 examined 219 Arab men and reported that there was an
inverse association between the two parameters.18 At present, we
cannot explain why our results are different from those studies,
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considerably larger than those of the previous studies. As another
explanation, the lower frequency of obese men in the present study
might have affected the results, but it may have limited impact.
Even when restricted to men with BMI 25 kg/m2, the APN levels
of the present participants with PSA levels  4 ng/mL were
signiﬁcantly higher than those of the participants with PSA< 4 ng/
mL (Fig. 2B). This ﬁnding also suggests that mechanisms unrelated
to obesity might be involved in the positive correlation between
APN levels and PSA levels.
Secondly, the APN levels of our participants who were diag-
nosed with PCA were signiﬁcantly higher than that of the partici-
pants with PSA< 4 ng/mL. Among the PCA patients, although the
difference was not signiﬁcant, the APN levels of the low- or inter-
mediate-risk PCA patients tended to be higher compared with
those of the high-risk PCA patients. Consequently, when restricted
to high-risk PCA patients, the APN levels were not signiﬁcantly
different from those of the participants with PSA< 4 ng/mL.
The relatively low APN levels of poor risk PCA patients pre-
sented here are in accordance with most of the previous case
control studies of PCA patients who underwent radical prostatec-
tomy. There have been at least six studies showing an inverse as-
sociation of APN levels and high-stage or high-grade PCA.9e14 It is
notable that the signiﬁcant association was observed only among
overweight and obese men in two of the six studies. In the present
study, we observed signiﬁcantly higher APN levels in the PCA pa-
tients compared with the participants with PSA< 4 ng/mL, how-
ever, this was limited to the low/intermediate-risk PCA patients.
Moreover, it should be emphasized that 69% of the participants
were normal or underweight men.
From this point of view, the results of a case control study
conducted by Nishimura et al15 are noteworthy in that the partic-
ipants had a BMI distribution similar to that of the present study. By
comparing Japanese PCA patients and benign prostatic hypertrophy
patients, Nishimura et al15 showed that patients with APN levels
higher than the median APN level had a signiﬁcantly elevated risk
of PCA after adjustment for body weight.15
Finally, we calculated the age-adjusted CDR of our participants
with stratiﬁed BMI (cut-off level of 25 kg/m2) and APN levels (cut-
off level of 6.7 mg/mL). Interestingly, the highest age-adjusted CDR
was observed in the men with higher BMIs and higher APN levels.
As expected, the CDR of the low/intermediate-risk PCA patients was
higher in the participants with APN 6.7 mg/mL compared with the
participants with lower APN. The difference in CDR by APN levels
was not observed in our high-risk PCA patients. Although the
sample size is relatively small for analyzing CDR, to our knowledge,
this is the ﬁrst report showing an increase in the CDR of PCA among
men with higher APN levels.
Recently, Medina et al16 reported notable results of a nested case
control study based on a prospective cohort including >4,000 men
who annually underwent PSA testing. A total of 228 cases (PCA
patients) and 239 controls were analyzed. Those authors showed
that the percentage of HMW-APN but not total APN levels had a
signiﬁcant relationship with PCA. More importantly, overweight
men (with a BMI between 25 kg/m2 and 30 kg/m2) had a higher
probability of PCA as the percentage of HMW-APN increased.
Interestingly, just the opposite association was observed in obese
men. It is notable that in the present study, 93% of the men with a
BMI 25 kg/m2 were overweight but not obese.
Several investigations have demonstrated the antitumor effect
of APN through antiproliferative and antiangiogenic effects in
various types of cancer.6 APN inhibited cell growth in both
androgen-dependent and -independent PCA cell lines.24 Therefore,
based on those in vitro data, it is difﬁcult to explain the positive
association of APN levels and PCA. Some authors speculated thatthe increased APN levels in cancer patients might be a protective
response against tumor progression,25 however, most of the pa-
tients in the present study were diagnosed with PCA at an early
stage. Although the exact mechanisms cannot be speciﬁed, the
positive correlation between APN levels and PSA levels might be a
clue to further understanding. It is possible that the positive cor-
relation of both parameters resulted in a detection bias in the
present PSA-based PCA screening, however, the proportion of
participants who underwent a biopsy did not differ between the
participants with APN 6.7 mg/mL and those with APN< 6.7 mg/mL
(2.07% and 2.24%, respectively, P¼ 0.77). Although the difference
was not signiﬁcant, the positive biopsy rates tended to be higher in
the participants with APN 6.7 mg/mL compared with those with
APN< 6.7 mg/mL (47.1% and 25.8%, respectively).Therefore, detec-
tion bias, if present, cannot explain the positive correlation be-
tween the APN levels and PSA levels presented here. It is of great
interest to investigate the regulatory role of APN in PSA secretion
and the interaction of APN with androgen-responsive elements.
Our study had several limitations. Because it was a cross-
sectional study, it was not possible to predict the causal relation
between APN levels and development of PCA. Prostate biopsy was
performed on 65 men. The reasons why only 65 persons received a
prostate biopsy were that we comprehensively determined the
indication, and also that some participants hesitated to undergo
biopsy. As expected in the PCA screening database, almost all pa-
tients were diagnosed in the early stage. In contrast with studies in
Western countries, the proportion of obese men with a
BMI> 30 kg/m2 was extremely low. This makes it difﬁcult to simply
extrapolate our results to a population with a different proportion
of obese men. Finally, we did not evaluate APN multimers, espe-
cially HMW-APN, the most biologically active isoform of APN.
In conclusion, using a large-scale cross-sectional study, we
demonstrated that there was a signiﬁcant positive correlation be-
tween APN levels and PSA levels. To the best of our knowledge, this
is the largest database that simultaneously analyzes both parame-
ters. The results of our study also suggest that the incidence of low-
or intermediate-risk PCA might be increased in overweight men
with high serum APN levels.Conﬂicts of interest
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